Publications by authors named "Suarez-Carantona C"
Article Synopsis
- Older people (80 years and up) are at risk for getting Clostridioides difficile infection (CDI) more often and it's usually more severe when they do.
- A study looked at patients with CDI from 2021 to 2022 to see how age affected recurrence and survival after treatment.
- They found that older patients had a higher chance of dying from CDI, even though the recurrence rates were similar for both age groups.
Article Synopsis
- Hospital A, with an infectious disease specialist program, had better management of CDI, avoiding unnecessary treatments and leading in guideline adherence compared to Hospital B.
- Both hospitals showed no significant differences in mortality and recurrence rates, but Hospital B had higher chances of patient readmission and emergency visits due to CDI.
- Overall, specialized CDI programs help improve patient care and may lead to more efficient use of hospital resources.
Objective: We aimed to test the non-inferiority of oral versus intravenous hydration in the incidence of contrast-associated acute kidney injury (CA-AKI) in elderly outpatients undergoing a contrast-enhanced computed tomography (CE-CT) scan.
Methods: PNIC-Na (NCT03476460) is a phase-2, single-center, randomized, open-label, non-inferiority trial. We included outpatients undergoing a CE-CT scan, >65 years having at least one risk factor for CA-AKI, such as diabetes, heart failure, or an estimated glomerular filtration rate (eGFR) of 30-59 mL/min/1.
Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.
Objectives: To study whether low-dose rituximab is also effective for bullous pemphigoid.
Methods: Patients with BP were treated with a single cycle of two infusions of rituximab 500 mg at an interval of 2 weeks.
Introduction: Cancer patients are more susceptible to infections, and infection can be more severe than in patients without cancer diagnosis. We conducted this retrospective study in patients admitted for SARS-CoV-2 infection in order to find differences in inflammatory markers and mortality in cancer patients compared to others.
Methods: We reviewed the electronic records of patients admitted for SARS-CoV-2 infection confirmed by PCR from March to September 2020.
Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.
Objectives: To study whether low-dose rituximab is also effective for bullous pemphigoid.
Methods: Patients with BP were treated with a single cycle of two infusions of rituximab 500mg at an interval of 2 weeks.
The availability of highly sensitive molecular tests for the detection of in feces leads to overtreatment of patients who are probably only colonized. In this prospective study, the usefulness of fecal calprotectin (fCP) is evaluated in a cohort of patients with detection of toxigenic in feces. Patients were classified by an infectious diseases consultant blinded to fCP results into three groups-group I, presumed infection (CDI); group II, doubtful but treated CDI; and group III, presumed colonization or self-limited CDI not needing treatment.
View Article and Find Full Text PDF